Nurix Therapeutics (NASDAQ:NRIX) Given "Buy" Rating at Needham & Company LLC

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They presently have a $29.00 target price on the stock. Needham & Company LLC's price objective indicates a potential upside of 13.81% from the stock's current price.

Several other research analysts have also recently issued reports on the stock. Robert W. Baird assumed coverage on shares of Nurix Therapeutics in a report on Friday, September 6th. They issued an "outperform" rating and a $26.00 target price for the company. Stephens reaffirmed an "overweight" rating and issued a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, October 14th. JPMorgan Chase & Co. lifted their target price on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an "overweight" rating in a report on Monday, July 15th. Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $41.00 price objective for the company. Finally, Truist Financial assumed coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They set a "buy" rating and a $36.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $29.00.

Nurix Therapeutics Trading Up 1.7 %

NASDAQ:NRIX traded up $0.43 on Monday, reaching $25.48. 598,308 shares of the stock traded hands, compared to its average volume of 896,165. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -8.73 and a beta of 2.22. Nurix Therapeutics has a 12 month low of $4.22 and a 12 month high of $26.43. The company's fifty day simple moving average is $23.81 and its 200 day simple moving average is $19.73.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). The business had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. Equities analysts anticipate that Nurix Therapeutics will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,408 shares of the company's stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $70,443.36. Following the completion of the sale, the insider now directly owns 45,150 shares of the company's stock, valued at approximately $933,250.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,408 shares of the company's stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $70,443.36. Following the completion of the transaction, the insider now directly owns 45,150 shares in the company, valued at $933,250.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 20,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total transaction of $504,400.00. Following the completion of the transaction, the chief financial officer now owns 31,002 shares of the company's stock, valued at approximately $781,870.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,105 shares of company stock valued at $1,507,181. Insiders own 7.20% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock worth $95,000 after acquiring an additional 3,424 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Nurix Therapeutics during the first quarter worth $123,000. ProShare Advisors LLC boosted its position in shares of Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company's stock worth $176,000 after acquiring an additional 998 shares during the last quarter. Dark Forest Capital Management LP bought a new position in shares of Nurix Therapeutics during the second quarter worth $201,000. Finally, Caxton Associates LP bought a new position in shares of Nurix Therapeutics during the first quarter worth $225,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.